HBM Healthcare

Funding rounds backed by HBM Healthcare.

Export CSV
Funding disclosed in full
$525M
Median round
$262.5M
Rounds in calculation
2
2 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
CellCentric

Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma

$220MSeries DBiotechUnited Kingdom
9 participantsAmerican Cancer Society BrightEdgeAvego BioScience CapitalFidelity Management & Research CompanyForbionHBM HealthcarePfizerRA Capital ManagementSofinnova PartnersVenrock Healthcare Capital Partners
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries FBiotechUnited States
23 participantsAlderline GroupARCH Venture PartnersCatalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners